Scientific Letter

Low-level viraemia despite emergence of dolutegravir-resistant variants

Johannes C. Botha, Kim Steegen, Mariam Edoo, Jeremy Nel, Gert U. van Zyl
Southern African Journal of HIV Medicine | Vol 23, No 1 | a1398 | DOI: https://doi.org/10.4102/sajhivmed.v23i1.1398 | © 2022 Johannes C. Botha, Kim Steegen, Mariam Edoo, Jeremy Nel, Gert U. van Zyl | This work is licensed under CC Attribution 4.0
Submitted: 03 May 2022 | Published: 30 September 2022

About the author(s)

Johannes C. Botha, Department of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
Kim Steegen, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, National Health Laboratory Service, Johannesburg, South Africa; and, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Mariam Edoo, Department of Medicine, Helen Joseph Hospital, Johannesburg, South Africa
Jeremy Nel, Department of Medicine, Helen Joseph Hospital, Johannesburg, South Africa; and, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa
Gert U. van Zyl, Department of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; and, Department of Molecular Medicine, National Health Laboratory Service, Cape Town, South Africa

Abstract

No abstract available.


Keywords

HIV; Dolutegravir; slow viremia decline; second line; INSTI naïve; drug resistance

Metrics

Total abstract views: 3099
Total article views: 3480

 

Crossref Citations

1. Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review
Kaiming Tao, Soo-Yon Rhee, Carolyn Chu, Ava Avalos, Amrit K. Ahluwalia, Ravindra K. Gupta, Michael R. Jordan, Robert W. Shafer
Viruses  vol: 15  issue: 9  first page: 1932  year: 2023  
doi: 10.3390/v15091932

2. High prevalence of reverse transcriptase inhibitors associated resistance mutations among people living with HIV on dolutegravir-based antiretroviral therapy in Francistown, Botswana
Ontlametse T Choga, Goitseone M Lemogang, Wonderful T Choga, Gaonyadiwe Muzanywa, Thembinkosi M Shadreck, Charity Ralegoreng, Dorcas Maruapula, Natasha O Moraka, Catherine K Koofhethile, Patrick T Mokgethi, Kedumetse Seru, Boitumelo J L Zuze, Patience Montshosi, Irene Gobe, Modisa S Motswaledi, Rosemary Musonda, Mpaphi B Mbulawa, Joseph Makhema, Roger Shapiro, Shahin Lockman, Tony Chebani, Judith Nawa, Lindani Bochena, Sikhulile Moyo, Simani Gaseitsiwe
Journal of Antimicrobial Chemotherapy  vol: 80  issue: 3  first page: 767  year: 2025  
doi: 10.1093/jac/dkae472

3. Beware of resistance to 2nd-generation integrase inhibitors: A systematic meta-analysis of HIV-1 integrase inhibitors resistance and drug resistance mutations
Shanshan Liu, Defu Yuan, Ying Zhou, Bei Wang, Haiyang Hu
International Journal of Antimicrobial Agents  vol: 64  issue: 3  first page: 107294  year: 2024  
doi: 10.1016/j.ijantimicag.2024.107294

4. Geospatial and temporal mapping of detectable HIV-1 viral loads amid dolutegravir rollout in KwaZulu-Natal, South Africa
Lilishia Gounder, Andrew Tomita, Richard Lessells, Sandrini Moodley, Kerri-Lee Francois, Aabida Khan, Melendhran Pillay, Sontaga C. Manyana, Subitha Govender, Kerusha Govender, Pravi Moodley, Raveen Parboosing, Nokukhanya Msomi, Frank Tanser, Kogieleum Naidoo, Benjamin Chimukangara, Sanjana Mukherjee
PLOS Global Public Health  vol: 4  issue: 5  first page: e0003224  year: 2024  
doi: 10.1371/journal.pgph.0003224

5. Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir
Ingrid A. Beck, Ceejay L. Boyce, Marley D. Bishop, Yen L. Vu, Amanda Fung, Sheila Styrchak, Nuttada Panpradist, Barry R. Lutz, Lisa M. Frenkel
Viruses  vol: 16  issue: 7  first page: 1162  year: 2024  
doi: 10.3390/v16071162